Core Viewpoint - Yuaneng Bio has officially launched its Series B financing and is actively preparing for its listing on the Sci-Tech Innovation Board, focusing on the automation of low-temperature storage technology in the cell industry [1][5]. Group 1: Company Overview - Yuaneng Bio has been dedicated to the automation of low-temperature storage for nearly eight years, achieving over 600 domestic and international patent applications, with more than 500 granted [1][2]. - The company aims to transform low-temperature storage technology from laboratory applications to industrialization, driven by policy, capital, and entrepreneurial efforts [1][4]. Group 2: Technological Innovations - The company has developed a groundbreaking "honeycomb" storage structure that physically isolates each sample to prevent cross-contamination, addressing industry challenges such as frost and contamination [2][3]. - Yuaneng Bio has introduced a series of products covering various temperature ranges and scenarios, successfully implemented in multiple projects across health and research institutions [2][3]. Group 3: Market Strategy and Future Plans - The company is transitioning from small-scale manufacturing to standardization and modularization of its products to reduce production costs and enhance efficiency [3][5]. - Yuaneng Bio is expanding its market presence domestically while also seeking to establish partnerships and expand its customer base internationally [3][5]. - The company plans to complete its intelligent manufacturing base in Shanghai in 2024, with a total area of nearly 10,000 square meters, to support its production capabilities [5][6]. Group 4: Industry Position and Vision - Yuaneng Bio is positioned as a leader in the intelligent cell biological sample storage industry, aiming to accelerate the application of its technology and promote industrial development [4][5]. - The company envisions a future where cell storage becomes a common practice for families, emphasizing the importance of cells as valuable life resources [5].